Your browser doesn't support javascript.
loading
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Chapman, P B; Robert, C; Larkin, J; Haanen, J B; Ribas, A; Hogg, D; Hamid, O; Ascierto, P A; Testori, A; Lorigan, P C; Dummer, R; Sosman, J A; Flaherty, K T; Chang, I; Coleman, S; Caro, I; Hauschild, A; McArthur, G A.
  • Chapman PB; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: chapmanp@mskcc.org.
  • Robert C; Department of Medicine, Institut Gustave Roussy and Paris Sud University, Paris, France.
  • Larkin J; Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.
  • Haanen JB; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Ribas A; Department of Medicine, Hematology and Oncology, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA.
  • Hogg D; Division of Medical Oncology and Hematology, Princess Margaret Hospital and University Health Network, Toronto, Canada.
  • Hamid O; The Angeles Clinic and Research Institute, Melanoma Therapeutics, Los Angeles, USA.
  • Ascierto PA; Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples.
  • Testori A; Melanoma and Sarcoma, Istituto Europeo di Oncologia, Milan, Italy.
  • Lorigan PC; Department of Medical Oncology, University of Manchester, Manchester, UK.
  • Dummer R; Department of Dermatology, University of Zurich, Zurich, Switzerland.
  • Sosman JA; Department of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA.
  • Flaherty KT; Department of Medicine, Massachusetts General Hospital, Boston, USA.
  • Chang I; Department of Biostatistics in Product Development, Biometrics, South San Francisco, USA.
  • Coleman S; Clinical Department, Oncology, Genentech Inc., South San Francisco, USA.
  • Caro I; Product Development, Oncology, Genentech Inc., South San Francisco, USA.
  • Hauschild A; Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.
  • McArthur GA; Department of Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia; Department of Oncology, University of Melbourne, Parkville, Australia.
Ann Oncol ; 28(10): 2581-2587, 2017 Oct 01.
Article en En | MEDLINE | ID: mdl-28961848
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Sulfonamidas / Proteínas Proto-Oncogénicas B-raf / Indoles / Melanoma / Mutación Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Sulfonamidas / Proteínas Proto-Oncogénicas B-raf / Indoles / Melanoma / Mutación Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2017 Tipo del documento: Article